Influenza News and Research

Latest Influenza News and Research

CSL Biotherapies comments on influenza vaccine paediatric adverse events

CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children. CSL is one of several suppliers of influenza vaccine in Australia.

23 Apr 2010

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product.

23 Apr 2010

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

The seasonal flu vaccine has caused serious side effects in dozens of children in Western Australia (WA) and following this the Health Department has suspended further free flu vaccinations for under-fives. There has been as rise in admissions to Princess Margaret Hospital. The side effects to the flu vaccine include fever, vomiting and often seizures related to high fever, also known as febrile convulsions. One of the children is seriously ill at present.

22 Apr 2010

Swine flu vaccine blues

Exactly a year after the swine flu outbreak vigilance, newer vaccine techniques and other measures are being emphasized by researchers and key decision makers. Dr. Harvey Fineberg, chairman of the World Health Organization's pandemic review committee and President of the U.S. Institute of Medicine says, we need to look at the past to learn from it.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

Inovio Biomedical wins Vaccine Industry Excellence Award in “Best Early Stage Biotech” category

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company was awarded a Vaccine Industry Excellence Award in the category of "Best Early Stage Biotech" by a panel of judges composed of a broad selection of biotech industry stakeholders. The award was presented at the World Vaccine Congress being held April 19 - 22, 2010, in Washington, D.C.

21 Apr 2010

Test shows efficacy of avian antibodies against H5N1 and H1N1 influenza in mice

Scientists have discovered for the first time that antibodies in common eggs laid by hens vaccinated against the H5N1 virus can potentially prevent a possible H5N1 pandemic, raising the possibility that the same principle could be applied to the current H1N1 influenza pandemic.

21 Apr 2010

Pregnant women face increased risk of death from H1N1; early antiviral treatment associated with fewer complications

Pregnant women had a disproportionately higher risk of death due to 2009 influenza A(H1N1) in the U.S., and early antiviral treatment appeared to be associated with fewer admissions to an ICU and fewer deaths, according to a study in the April 21 issue of JAMA.

21 Apr 2010

IMPACT trial shows improvement in OS for metastatic CRPC

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

21 Apr 2010

Meridian Bioscience's second-quarter net sales down 6% to $31.1M

Net sales for the second quarter of fiscal 2010 were $31,147,000 as compared to $33,280,000 for the same period of the prior fiscal year, a decrease of 6%. Net earnings for the second quarter of fiscal 2010 were $5,980,000 or $0.15 per diluted share, decreases of 18% and 17%, respectively, compared to the second quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,177,000 and 41,133,000, respectively.

20 Apr 2010

Medical device industry leaders to meet with lawmakers, government officials at MDMA annual meeting

As the U.S. Food and Drug Administration is reviewing pivotal regulatory procedures for one of America's fastest growing sectors, industry leaders will gather to meet with lawmakers and government officials at the 16th Annual Meeting of the Medical Device Manufacturers Association on May 24-26, 2010 at the Park Hyatt in Washington, DC.

20 Apr 2010

UnitedHealth Group's consolidated first-quarter 2010 revenues increase 5% to $23.2 billion

UnitedHealth Group today reported first quarter results, including better-than-projected membership and services growth and effective cost management across its businesses. Financial metrics were in line with or better than Company expectations.

20 Apr 2010

National health care reform package promises to reduce number of uninsured Americans

The national health care reform package signed by President Obama recently promises to significantly reduce the number of uninsured Americans. According to the Congressional Budget Office, 31 million Americans who are currently uninsured will gain health care coverage under the federal legislation.

20 Apr 2010

Forgetfulness, procrastination related to prescription drugs costs $163 billion in wasteful healthcare spending

Express Scripts is the first organization ever to quantify the hidden healthcare costs of very common behaviors related to prescription drugs, such as forgetfulness and procrastination, estimating the annual wasteful spending at $163 billion.

20 Apr 2010

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

Though the world has made "great strides" in eliminating H5N1 (avian flu) from poultry since the "peak of its outbreak in 2006" in 63 countries, the virus persists in Bangladesh, China, Egypt, Indonesia and Vietnam, VOA News reports (DeCapua, 4/16).

20 Apr 2010

PRA International expands clinical research operations to New Zealand

PRA International, a leading Clinical Research Organization, announces it has established a legal entity and hired staff in New Zealand, which will complement the firm's extensive network of Asia-Pacific operations and partnerships.

19 Apr 2010

MinuteClinic helps patients take control of allergies with treatment services seven days a week

As trees blossom and shed their pollen and grasses and weeds germinate in yards and fields across America, allergy sufferers are retreating indoors with seemingly no relief in sight. MinuteClinic, the walk-in medical clinic inside select CVS/pharmacy stores, can help patients breathe easier and take control of their allergies this spring with treatment services available seven days a week, including weekday evening hours.

16 Apr 2010

Seasonal flu tends to move in traveling waves: Researchers

An analysis of hospitalization records for adults age 65 and over found that seasonal flu tends to move in traveling waves, peaking earliest in western states such as Nevada, Utah, and California and working its way east. New England states such as Rhode Island, Maine, and New Hampshire tend to have the latest peak in seasonal flu, according to public health researchers at Tufts University in Boston.

16 Apr 2010

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress™ 2010, the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

16 Apr 2010

Influenza News and Research

Latest Influenza News and Research

CSL Biotherapies comments on influenza vaccine paediatric adverse events

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

Swine flu vaccine blues

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Inovio Biomedical wins Vaccine Industry Excellence Award in “Best Early Stage Biotech” category

Test shows efficacy of avian antibodies against H5N1 and H1N1 influenza in mice

Pregnant women face increased risk of death from H1N1; early antiviral treatment associated with fewer complications

IMPACT trial shows improvement in OS for metastatic CRPC

Meridian Bioscience's second-quarter net sales down 6% to $31.1M

Medical device industry leaders to meet with lawmakers, government officials at MDMA annual meeting

UnitedHealth Group's consolidated first-quarter 2010 revenues increase 5% to $23.2 billion

National health care reform package promises to reduce number of uninsured Americans

Forgetfulness, procrastination related to prescription drugs costs $163 billion in wasteful healthcare spending

NanoBio to develop intranasal vaccine for HBV

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

PRA International expands clinical research operations to New Zealand

MinuteClinic helps patients take control of allergies with treatment services seven days a week

Seasonal flu tends to move in traveling waves: Researchers

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Influenza News and Research

Latest Influenza News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in